ArticleOncoimmunology2015

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

Friedrich H Schmitz-Winnenthal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.